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Abstract: In photodynamic therapy (PDT) a photosensitizer –  a molecule that is activated by 
light – is administered and exposed to a light source. This leads both to destruction of cells targeted 
by the particular type of photosensitizer, and immunomodulation. Given the ease with which 
photosensitizers and light can be delivered to the skin, it should come as no surprise that PDT   
is an increasingly utilized therapeutic in dermatology. PDT is used commonly to treat precancer-
ous cells, sun-damaged skin, and acne. It has reportedly also been used to treat other conditions 
including inflammatory disorders and cutaneous infections. This review discusses the principles 
behind how PDT is used in dermatology, as well as evidence for current applications of PDT.
Keywords: photodynamic therapy, skin cancer, actinic keratosis, acne, aminolevulinic acid, 
methylaminolevulinate
Introduction
Photodynamic therapy (PDT) is a therapeutic method used with increasing frequency in 
dermatology. In the US, PDT is approved for the treatment of thin actinic keratoses, but 
off-label uses continue to increase.1 The concept of PDT is deceptively simple, in that 
it requires only three ingredients, ie, a photosensitizer, a light source, and oxygen. The 
therapeutic effect is achieved by light activation of a photosensitizing agent, and in the 
presence of oxygen, reactive oxygen intermediates are formed. These intermediates 
irreversibly oxidize essential cellular components, causing apoptosis and necrosis.2,3 
PDT is safe and effective, and produces excellent cosmetic results with few adverse 
effects. It has the advantage of allowing application to multiple lesions. Pain, edema, 
erythema, pigmentation, and pustules are among the main complications, with the 
most common complaint being pain during delivery of treatment.4,5 In this paper, we 
review the evidence for current applications of PDT in dermatology.
History
At the beginning of the 20th century, Oscar Raab, a medical student, serendipitously 
discovered the toxic effect of cumulative acridine orange (a photosensitizer) and light 
on Paramecium caudatum cells. He confirmed his findings by testing the components 
individually, with no apparent damaging effect on the protozoa separately. His profes-
sor, Von Tappeiner, worked in collaboration with Jesionek, a dermatologist, on the first 
clinical trial, which was conducted in 1903 using eosin and light to treat the cutane-
ous manifestations of diseases such as condylomata lata, lupus vulgaris, psoriasis, 
stage II syphilis, and non-melanoma skin cancer.6,7 Von Tappeiner referred to this as 
“photodynamic therapy”.8,9 Despite this breakthrough, PDT was not widely used until Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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the mid 1970s. For example, in 1975, Thomas Dougherty dis-
covered that administration of a hematoporphyrin derivative 
and red light obliterated mammary tumor growth in mice.10
Mechanism
PDT requires three essential components: a photosensitizer, 
a light source, and oxygen. The photosensitizer is a molecule 
that localizes to the target cell and/or tissue and can only be 
activated by light. When the photosensitizer is exposed to 
specific wavelengths of light, it becomes activated from a 
“ground state” to an “excited state” (Figure 1). As it returns 
to the ground state, there are two ways in which the energy 
released can mediate selective cell killing. First, it can react 
with the substrate to form radicals, which further interact 
with oxygen to produce oxygen free radicals (type I reaction). 
Or the energy can be directly transferred to oxygen to form 
singlet oxygen (1O2), a subset of reactive oxygen species, 
which then oxidizes various substrates (type II reaction) and 
thus mediates selective cell killing.3 Type II photochemical 
reactions are thought to predominate in PDT.11 Damage to 
surrounding healthy tissue can be minimized by modifying 
the selectivity of uptake and directing the duration and depth 
of the light source. Selectivity of PDT is determined by 
several factors, including: uptake of the photosensitizer into 
target cells/tissue; metabolism of the agent to its active form; 
and penetration and selectivity of the light source. Given 
these variables, the clinical reaction for each individual can 
be difficult to predict.
Phototoxic effects occur through intracellular localization 
of the photosensitizer and surrounding immunologic effects. 
Porphyrins are mainly localized in mitochondria, that lead 
to apoptosis or necrosis upon light exposure.7,12–14 Immune-
specific responses include production of interleukin 1-beta, 
interleukin 2, tumor necrosis factor-alpha, and granulocyte 
colony-stimulating factor. PDT generally has a low potential 
for causing DNA damage, mutation, or carcinogenesis.15
Clinical delivery
Photosensitizers
There are many types of photosensitizers available and 
several routes (topical, oral, or intravenous) by which they 
can be delivered to the patient. Currently, the only photosen-
sitizers approved by the US Food and Drug Administration 
for dermatologic indications are aminolevulinic acid (ALA) 
and methyl aminolevulinate (MAL). Both drugs are prodrugs 
that require conversion to porphyrin. After topical applica-
tion of the photosensitizer, an “occlusion time” is permitted 
for the drug to be metabolized and accumulate porphyrins 
before light activation. Ultimately, porphyrin serves as the 
photosensitizer.
Most cells in the human body can metabolize ALA 
or MAL into photoactivatable porphyrins, in particular 
protoporphyrin IX, but the levels vary between tissue and 
cell types. For example, porphyrins accumulate mostly in 
sebaceous glands and in the epidermis and preferentially 
in dysplastic cells and hyperproliferative tissue.16–18 The main 
barrier to the absorption of photosensitizers is the stratum 
corneum.19 ALA crosses the cell membrane, and conver-
sion to protoporphyrin IX occurs intracellularly. However 
ALA esters, such as MAL, are first hydrolyzed to ALA in 
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Figure 1 Schema of a photochemical reaction during photodynamic therapy. Absorption of photons from a light source results in energy transfer to the photosensitizer. The 
photosensitizer moves from a ground state to an excited state. The energy released (as it returns to ground state) mediates cellular cytotoxicity.Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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the cytosol. ALA is then converted to protoporphyrin IX 
physiologically as part of the heme cycle.20 This extra conver-
sion is thought to result in a delay in onset of MAL photosen-
sitization, and therefore the incubation period for MAL needs 
to be longer. Additional factors, such as temperature, also 
affect the efficiency of protoporphyrin IX production in that 
higher temperatures facilitate conversion.21 Quenching of the 
existing photosensitizer is known as photobleaching, which 
results in what is visualized as fluorescence. For instance, 
using a camera with a filter for excitation (415 nm) and a 
filter for emission (635 nm) allows detection of the amount 
of photosensitizer in the tissue (Figure 2). The intensity of 
the measured fluorescence represents photosensitizer uptake 
and, correspondingly, can predict PDT tissue damage. In the 
future, utilization of such technology may help clinicians to 
determine the parameters for PDT (for example, length of 
incubation or fluence delivered from the light source).22
Aminolevulinic acid
The only approved indication for ALA (Levulan®, DUSA 
Pharmaceuticals Inc) is for the treatment of hypertrophic 
actinic keratoses on the face and scalp in combination 
with blue light in North America. In Europe, a patch con-
taining ALA (Alacare®, Spirig Pharma AG, Egerkingen, 
  Switzerland) and a gel formulation ALA with nanoemul-
sion (Ameluz®, Spirit Healthcare Ltd, Oadby, UK) are also 
licensed for treatment in combination with red light. ALA 
is unstable as an aqueous formulation because it has low 
lipid solubility, limiting its ability to penetrate through 
skin or cell membranes and thus restricting its use in PDT 
to superficial disease.23 One study demonstrated that ALA 
was able to penetrate up to 2 mm deep in nodular basal cell 
carcinoma (BCC).17 Novel preparations of ALA, particularly 
the nanoscale vesicle formulation, have been shown to chemi-
cally stabilize the drug and increase liposomal penetration. 
For instance, nanoemulsion/nanocolloidal formulations of 
this drug have been observed to be superior to methyl ester 
methyl aminolevulinate in the treatment of actinic keratoses 
(complete clearance 78.2% versus 64.2%, respectively) 
and field cancerization.24–26 In Europe, BF-200 ALA (an 
approved nanoemulsion formulation of 5-ALA) has been 
studied extensively.
Methyl aminolevulinate
A derivative of ALA, methyl ester methyl aminolevulinate, 
MAL (Metvixia®, Galderma SA, Lausanne, Switzerland) is 
available in a cream form and is approved in the US for the 
treatment of nonhyperkeratotic actinic keratoses of the face 
and scalp in immunocompetent patients. MAL (Metvix®, 
  Galderma SA) is also approved in several European coun-
tries, New Zealand, and Australia for both superficial and 
nodular BCC. MAL is also approved in Europe for squamous 
cell carcinoma (SCC) in situ, also known as Bowen’s dis-
ease, when surgical excision is considered less appropriate, 
including for cosmetic purposes.
MAL is reported to have increased lipophilicity and 
deeper skin penetration when compared with ALA. However, 
there was no statistically significant difference in efficacy 
between ALA and MAL in the treatment of nodular BCC in 
one small pilot study or in the treatment of actinic keratosis 
Figure  2  (A)  Digital  photograph  of  facial  skin  from  a  patient  with  nevoid 
basal  cell  carcinoma  (Gorlin-Goltz)  syndrome.  (B)  Fluorescence  photography 
using ∼510 nm excitation and ∼633 nm emission filters after 3 hours of incubation 
with 5-aminolevulinic acid under occlusion. (C) Overlap of (A and B) to highlight 
porphyrin accumulation in red. Note intense epidermal fluorescence beyond clinical 
tumor margins. Images courtesy of Fernanda H Sakamoto and R Rox Anderson, 
wellman  Center  for  Photomedicine,  Massachusetts  General  Hospital,  Harvard 
Medical School, Boston, MA, USA.Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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in another randomized trial.27–29 In theory, MAL may be more 
selective than ALA in its affinity for lipophilic environments 
such as sebum, and thus would be predicted to have greater 
efficacy in the treatment of acne.18
Other ALA derivatives are the subject of ongoing 
research. Long-chain esters, such as heptyl esters, are capable 
of achieving the same protoporphyrin IX fluorescence induc-
tion at much lower concentrations than pure ALA.30 Further, 
several new photosensitizers (hypericin, indocyanine green, 
and indole-3-acetic acid) have been assessed in cutaneous 
oncologic diseases and are in the commercial pipeline.31–36
Light source and methods  
of delivery
The range of light sources is virtually limitless, and includes 
broad-spectrum continuous-wave light sources (blue, red, 
green light), incoherent polychromatic sources (gas discharge 
lamps, light-emitting diodes) or coherent monochromatic 
sources (intense pulsed light [IPL], potassium titanyl phos-
phate lasers, pulsed dye lasers, infrared lasers), PDT, photo-
pneumatic technology, and daylight have all been studied.
To generate a therapeutic effect, the spectral output of the 
light source should correspond to the excitation peaks of the 
photosensitizer. Protoporphyrin IX has two important peaks,   
404–420 nm and 635 nm in the blue (Soret band) and red 
wavelength regions of the visible spectrum, respectively. The 
US Food and Drug Administration has approved the Blu-U® 
(Blue Light Photodynamic Therapy Illuminator Model 4170, 
DUSA Pharmaceuticals Inc, Wilmington, MA, USA) device, 
which emits blue wavelengths of the light spectrum for use 
with ALA and other devices, including the red light spectral 
output to be used in conjunction with MAL. The depth of light 
penetration into the skin increases with longer wavelengths. 
Although blue light allows sufficient tissue penetration for the 
treatment of thin actinic keratoses, red light penetrates deeper 
and is more effective for the treatment of thicker lesions and 
deeper targets such as the sebaceous gland.
In comparison trials, employing continuous wave light 
sources is more efficacious than pulsed light sources.37 
Increasingly, white light sources, including direct sunlight, 
have also been utilized.38–43 In one careful study of MAL-PDT 
in the treatment of actinic keratoses, with long-term follow-
up, a light-emitting diode was the more effective light source 
as compared with white light.44 Nonetheless, an interesting 
avenue of research involves utilizing sunlight as the light 
source, which has the advantage of being accessible and 
does not occupy office space. The main advantage of using 
sunlight is the reduction in pain, given that photoactivation 
takes place over a longer period of time. Recent studies 
suggest that sunlight is effective as a light source for the 
treatment of actinic keratosis.41
Preparatory steps, particularly in the treatment of hyper-
trophic actinic keratoses, can improve photosensitizer uptake. 
The most recent studies include use of keratolytics, curettage/
debulking, tape stripping, microdermabrasion, and laser 
ablation.21,45,46 One split-face study demonstrated slightly 
superior efficacy and long-term improvement of actinic kera-
toses when using microneedling as a delivery system.47 Use of 
microneedling in SCC in situ and BCC failed to demonstrate 
either increased fluorescence uptake or clinical superiority. 
Nonetheless, SCC in situ and BCC are lesions that may not 
derive additional benefit from surface preparation, given their 
already compromised surface. Another study from Denmark 
demonstrated that use of a fractionated CO2 laser and PDT 
was significantly more effective than PDT alone at 3-month 
follow-up for all grades of severity in actinic keratosis.48
Contraindications and side effects
Contraindications to PDT include a nonresponsive tumor, 
a history of porphyria, systemic lupus erythematosus, photo-
sensitive dermatoses, and allergy to the active ingredients in 
the photosensitizer, which is considerably rare.
Common side effects of PDT include erythema, 
edema, itching, epithelial exfoliation, pustules, and post-
inflammatory hyperpigmentation, especially for Fitzpatrick 
skin phototype IV–V .49 The most common complaint from 
patients is pain during administration of phototherapy.50–52 
Some pain studies have indicated that ALA induces more 
pain as compared with MAL, while others have assessed the 
pain to be similar between the two photosensitizers.28,53,54
PDT in neoplastic disease
Actinic keratoses
Actinic keratoses are rough, scaly lesions in chronically 
ultraviolet-exposed areas which can progress to SCC. Most 
SCCs arise from actinic keratoses, and various progression 
rates have been reported. These lesions often occur in 
multiples and are generally associated with alteration of 
surrounding skin (field) in a phenomenon known as “field 
cancerization”.55,56 Topical 5-fluorouracil (5%, 1%, 0.5%), 
imiquimod cream (5%, 3.75%), ingenol mebutate (0.05%, 
0.015%), diclofenac sodium gel 3% with 2.5% hyaluronic 
gel, topical retinoids, chemical peels, lasers (ablative 
resurfacing with carbon dioxide) or erbium:yttrium alumi-
num garnet (YAG) and PDT are aimed at treating multiple 
lesions.Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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Studies on the treatment of actinic keratoses are notori-
ously difficult to perform. Quantitation of actinic keratoses 
before and after treatment is hindered by the fact that 
actinic keratoses can appear and disappear spontaneously. 
The literature on PDT for actinic keratoses is daunting, but 
convincingly, ALA-PDT is an effective treatment for actinic 
keratoses, with an excellent cosmetic outcome, especially 
compared with 5-fluorouracil and cryotherapy.57 One recent 
meta-analysis, which included 32 publications, found that 
ALA-PDT (blue light: relative risk [RR] 6.22, red light: RR 
5.94,) or MAL-PDT (red light: RR 4.46,) was superior to 
placebo-PDT for treatment of individual lesions. Based on 
participant-observed complete clearance in eight interven-
tions, efficacy from most effective to least effective was 
5-fluorouracil . ALA-PDT ∼ imiquimod ∼ ingenol mebu-
tate ∼ MAL-PDT . cryotherapy . diclofenac . placebo.58
ALA-PDT with blue light is the standard for treatment 
of actinic keratosis, but multiple protocols exist. At our 
institution, ALA is applied for a one-hour incubation under 
occlusion prior to blue light exposure (10 J/cm2). The use of 
a 5-ALA self-adhesive patch may eliminate discrepancies in 
ALA application. Red light has also been used for the treat-
ment of actinic keratoses. One randomized controlled study 
found that complete clearance of actinic keratoses 8 weeks 
after treatment occurred with 4-hour incubation of the self-
adhesive ALA patch (86% of actinic keratosis lesions) and 
red light therapy. Shorter incubation times at 2 hours (73%), 
one hour (72%), and half an hour (51%) proved to be subpar.59 
In one Phase III study, the 5-ALA patch-PDT without crust 
removal proved superior (82% and 89%) to placebo-PDT 
(19% and 29%, P,0.001) and cryosurgery (77%) in improve-
ment of actinic keratosis lesions on the scalp.60
Use of PDT has evolved from its application as mono-
therapy to an adjunct with other treatments. The value of 
sequential treatment with MAL-PDT and imiquimod was 
investigated in a randomized trial (n=105). Better response 
rates were seen for combination treatment than for either 
monotherapy; however, the difference in response was statisti-
cally significant only for the comparison between combina-
tion therapy and MAL-PDT monotherapy.61
Squamous cell carcinoma
Management of SCC is categorized by metastatic potential, 
ie, low-risk cutaneous SCC or high-risk (aggressive) cutane-
ous SCC, where surgical excision is the gold standard for the 
latter. Current therapies for SCC include surgical excision 
(Mohs surgery), cryotherapy, electrosurgery, topical treat-
ments (5-fluorouracil and imiquimod), radiation therapy, 
and PDT. PDT is only recommended for treatment of SCC 
in situ, and not for the treatment of invasive SCC.5,62
PDT demonstrated superior efficacy and less scarring 
in the treatment of SCC in situ when compared with cryo-
therapy or 5-fluorouracil in a Cochrane review (n=363).63 In 
particular, ALA-PDT appeared to have greater efficacy than 
5-fluorouracil but MAL-PDT was not demonstrated to be 
superior over 5-fluorouracil. Also, there was no difference 
in recurrence rates at 12 months with either MAL-PDT or 
ALA-PDT when compared with 5-fluorouracil.64 There are 
no randomized controlled trials directly comparing treatment 
with ALA-PDT versus MAL-PDT. The efficacy of PDT for 
SCC in situ was illustrated by a trial in which 225 patients 
were randomly assigned to two treatments of MAL-PDT 
(160 mg/g) with red light (570–670 nm, 75 J/cm2), PDT 
using a placebo, or conventional treatment (either cryotherapy 
or topical 5-fluorouracil). The lesion complete response 
rate at 12 months showed that MAL-PDT was superior to 
cryotherapy (80% versus 67%; odds ratio 1.77) and also bet-
ter than 5-fluorouracil (80% versus 69%; odds ratio 1.64). 
Cosmesis at follow-up was excellent in 94% of patients 
treated with MAL-PDT versus 66% with cryotherapy and 
76% with 5-fluorouracil. However, lesion recurrence rates 
at 12 months were similar with MAL-PDT, cryotherapy, and 
topical 5-fluorouracil (15%, 21%, and 17%, respectively).65 
There was also no significant difference in efficacy between 
MAL-PDT and 5-fluorouracil in the treatment of SCC in situ 
in immunosuppressed individuals.66
Several studies have looked at varying light sources. An 
observational study (n=53), using MAL-PDT, occlusion 
for 3 hours, and red light (630 nm, 38 J/cm2, 7.5 minutes) 
demonstrated that 76% of the lesions achieved a complete 
response after two sessions with a medium follow-up of 
16.6 months.62 There appears to be no superiority of ALA-
PDT with two-fold illumination (light treated at 4 and 6 hours 
with 20 and 80 J/cm2) versus single illumination (light treated 
at 4 hours with 75 J/cm2).67,68 There was also no statistically 
significant difference between ALA-PDT with red light or 
green light regarding clearance of lesions, but there were 
significantly fewer recurrences at 12 months of lesions treated 
with red light.
In summary, PDT can be considered for treatment of 
SCC and SCC in situ when there are multiple lesions, in 
an area where multiple surgeries would result in morbidity 
(for example, the lower extremities), or when lesions are 
known to be noninvasive. For optimal treatment, red light 
should be utilized. MAL-PDT achieves better penetration 
and has been shown to be more effective than ALA-PDT. Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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Multiple treatments can also increase efficacy. PDT rep-
resents an attractive option for superficial SCC given its 
improved cosmetic profile and similar recurrence rate when 
compared with cryotherapy or 5-fluorouracil. However, due 
to the metastatic potential and reduced efficacy rates, PDT 
cannot be recommended for invasive SCC.
Basal cell carcinoma
Current treatment for BCC includes Mohs micrographic 
surgery, excisional surgery, curettage and electrodessication, 
radiation, cryotherapy, PDT, laser therapy, topical treatments 
(imiquimod and 5-fluorouracil), and vismodegib (Erivedge®, 
Roche Pharmaceuticals, Basel, Switzerland). Generally, PDT 
is recommended as a treatment option for superficial and thin 
nodular BCC (thickness ,2 mm). However, some investiga-
tors accept 2–3 mm thick BCC for PDT when combined with 
pretreatment of lesion curettage. Preparation of the lesion 
prior to treatment is common, and more important for nodular 
BCC. Superficial debridement in a manner insufficient to 
cause pain is a common practice; some clinicians perform 
this weeks or hours in advance. One study showed a complete 
response, with histologic confirmation in 22 of 24 lesions 
(92%) treated with PDT and prior debridement.69,70
ALA-PDT treatment of BCC
A 10-year longitudinal study that reviewed clinical and 
histopathologic examination of 60 lesions found that the 
complete response rate for primary lesions after superficial 
curettage was 78%, with 63% after one session and 90% after 
two sessions. This study used ALA-PDT with halogen light 
(light intensity 150–230 mW/cm2). The cosmetic outcome 
was rated as good or excellent in over 91% of the evalu-
ated cases.71 Another study (n=94) compared the complete 
response rate (mean follow-up 25 months) for superficial 
BCC in patients who received ALA-PDT (31/31, 100%) ver-
sus surgery (28/29, 96.55%). Patients with nodular BCC had 
better response rates with surgery (16/17, 94.12%; P=0.88) 
than those treated with ALA-PDT (15/17, 88.24%).72
Blue light PDT alone for BCC is controversial because 
lesions with a vertical growth greater than 2 mm have not 
been studied extensively. Clinicians should use ALA-PDT 
with caution for treatment of BCC, especially nodular BCC, 
because ALA-PDT did not seem to be an effective option 
for treatment of nodular BCC in one randomized controlled 
trial (n=173) with 3-year follow-up; recurrence rates for 
surgical excision (2.3%) were substantially less compared 
with PDT (30.3%).73 However, combined therapy of ALA-
PDT and 5% imiquimod has been suggested to achieve a 
15% improvement in complete remission of nodular BCC 
compared with ALA-PDT alone.74
MAL-PDT in treatment of BCC
One noninferiority trial reported no significant difference 
between MAL-PDT and cryotherapy in the treatment of 
superficial BCC.75 Another trial showed that MAL-PDT 
was not inferior to surgery for treatment of nodular BCC 
at 3-month and 24-month follow-up.76 One French group 
confirmed that, at 3 months, the treatment difference 
(cryotherapy versus MAL-PDT) was -2.2% (P=0.49). At 
5 years, the overall lesion recurrence rate was 22% with 
MAL-PDT and 20% with cryotherapy.77 Szeimies et al 
determined that, at 3 months, the mean lesion count reduction 
was 92.2% for MAL-PDT versus 99.2% for surgery but this 
difference did not achieve statistical significance. Signifi-
cantly, at 12 months, however, 9.3% of lesions (11 of 118) 
recurred in the MAL-PDT group versus none in the surgery 
group (0 of 117).77 Although MAL-PDT is noninferior to 
cryotherapy and surgery, the cosmetic advantage associated 
with MAL-PDT is of great interest for low-risk superficial 
BCC, because lesions are often multiple, typically affecting 
skin sites predisposed to dystrophic scarring (such as the 
trunk).78–80
In randomized trials comparing different treatment 
modalities for BCC, a recent study demonstrated increased 
efficacy of imiquimod over MAL-PDT (83.4% versus 72.8%) 
at 12-month follow-up. This again argues for the advantage 
of using combination therapies with PDT, namely adding on 
imiquimod after treatment.81
A consensus group in Canada and Europe analyzed nine 
studies and report that use of MAL-PDT can be considered as 
a safe and effective treatment for BCC in patients with Gorlin 
syndrome, the efficacy being proportionate to the thickness of 
the lesion.82 PDT has been observed to have chemopreventive 
effects in patients with Gorlin syndrome.83,84
Cutaneous T cell lymphoma
PDT has been widely used in the treatment of mycosis fun-
goides, an indolent subtype of cutaneous T cell lymphoma. 
A few studies and various case reports have reported 
complete or partial responses in the treatment of mycosis 
fungoides. Most of these report efficacy of MAL-PDT and 
ALA-PDT in the treatment of plaque-type (stage I) myco-
sis fungoides, but decreased efficacy against tumor-type 
(stage II) mycosis fungoides, and there has been a single 
report of erosive mycosis fungoides on the face treated 
successfully with ALA-PDT using red light.70,85–89 As is Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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true for other skin tumors, PDT is less effective in deep or 
tumor-stage lesions. One prospective study (n=29) reported 
an objective response in 75% of plaque or patchy lesions 
after monthly treatments for 6 months.90 However, a recent 
study observed two of five patients who appeared to have 
had a complete response initially, but relapsed at follow-
up (10.0±10.5 months).91 MAL-PDT was successful in 
treatment-refractory mycosis fungoides (four patients with 
complete remission and one with partial remission).92 In 
conclusion, several consecutive treatments of PDT can be 
considered as an adjunct for treatment of mycosis fungoides, 
particularly for patch and plaque-stage mycosis fungoides, 
with good cosmetic results in sensitive skin areas.
Other tumors
PDT has also been reported in the treatment of Kaposi’s sar-
coma, extramammary Paget’s disease, and cutaneous B cell 
lymphoma.93 Other proliferative disorders, such as vascular 
malformations, have also been treated with impressive 
results, likely due to the antiangiogenic effects of PDT.94
PDT in inflammatory diseases
Acne vulgaris
The most common dermatologic disorder, acne vulgaris, is 
thought to be primarily caused by the obstruction of seba-
ceous glands, leading to proliferation of bacteria, mainly 
Propionibacterium acnes. P . acnes naturally produces 
porphyrins (protoporphyrin IX and coproporphyrin III), 
so light sources alone (blue light . red light) can have a 
direct therapeutic photodynamic effect.95 It is hypothesized 
that once applied to the skin, ALA and MAL are preferen-
tially taken up by the pilosebaceous unit and augment the 
response to light therapy. The available treatments for acne 
currently include salicylic acid, topical retinoids, benzoyl 
peroxide, sulfur, alpha hydroxy acids, and various light 
therapies.96,97
ALA-PDT and MAL-PDT with a light-emitting diode 
are commonly used as off-label treatments for acne. In gen-
eral, inflammatory lesions respond well to PDT, whereas 
comedonal/noninflammatory lesions tend to show no signifi-
cant change (Table 1). The literature has focused primarily 
on MAL-PDT followed by red light because targeting of 
the sebaceous glands is optimized with this regimen. In 
practice, however, this treatment tends to be painful, with 
increased edema and milium formation. It should be noted 
that a 180-minute incubation time maximizes production of 
porphyrin in the sebaceous glands and leads to longer remis-
sion of acne (Figure 3). In a split-face study, there was no 
significant difference in efficacy between ALA-PDT plus 
red light (34 J/cm2) and MAL-PDT plus red light (34 J/cm2) 
with 3-hour incubation times.98 Nonetheless, regimens using 
short incubation times (30–60 minutes) followed by blue light 
and/or IPL persist because they tend to be well tolerated. In 
these cases, frequent treatments are recommended. Such 
regimens have an advantage in Fitzpatrick skin types IV–VI 
because post-inflammatory hyperpigmentation is reduced. 
There may even be a role for ALA-PDT followed by IPL in 
the reduction of comedonal acne.
ALA-PDT in acne
The efficacy of PDT in acne was first described in a study 
of 22 patients, where 20% ALA was applied topically to the 
back with 3-hour occlusion followed by red light irradiation. 
This regimen was shown to reduce inflammatory acne lesions 
after multiple treatments (four treatments at one-week 
intervals) when compared with the other treatment groups 
(ALA alone, red light alone, untreated control) and compared 
with single PDT treatment in the respective study groups. 
After application of ALA, immunofluorescence revealed 
accumulation of porphyrin in areas of acne. Improvement 
initially was observed at 3 weeks following treatment, and 
was marked histologically by atrophic sebaceous glands, 
a granulomatous reaction, obliterated follicles, and perifol-
licular fibrosis. By the end of the study, there was complete 
destruction or a 45% decrease in sebaceous gland size. In this 
particular study, red light alone did not produce a therapeutic 
effect.99 Other small studies have also confirmed that inter-
val treatment of ALA with varying occlusion times (3 and 
4 hours) followed by red light is a highly effective treatment 
for acne (Table 1).99–102
The mechanism of ALA-PDT is thought to be due to 
selective destruction of the sebaceous unit after uptake of 
the photosensitizer, so the longest wavelengths capable of 
activating porphyrins (red light, 635 nm) have been utilized 
to target the sebaceous glands in the dermis. Most studies 
have focused on ALA with red light, but a few studies 
have also suggested that blue light PDT has increased 
efficacy compared with blue light alone in the treatment 
of acne.103 Nonetheless, in vitro studies comparing ALA 
followed by blue light (415 nm) or red light (635 nm) and 
examining the bactericidal effects on P . acnes, found that 
red light phototherapy was less effective for the eradica-
tion of P . acnes than blue light phototherapy with and 
without ALA.104 Therefore, there may still be a role for 
combined blue and red light activation of ALA in the 
treatment of acne.Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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Table 1 Comparative studies on PDT light sources in treatment of acne
Reference N Type of trial; study  
population/type
Light source (dose);  
incubation time
Session number  
(interval); follow-up
Results
Pinto  
et al176 
2013
36 Prospective, controlled, 
investigator-blinded; mild-
to-moderate acne
MAL-PDT versus red  
light (average wavelength  
635 nm, light dose 37 J/cm2, 
fluence rate approximately 
70 mw/cm2) alone;  
90 minutes
2× (2 weeks);  
10 weeks
MAL-PDT . red light alone: greater and  
more rapid clinical and histologic responses 
in MAL-PDT than red light only group.  
Histologically, decreased amount of  
sebocytes, lipids, and atrophic sebaceous  
glands. week 10, MAL-PDT (100%), red  
light only (77.7%) achieved successful  
treatment.
Hong et al49 
2013
20 Split-face, Fitzpatrick  
skin phototypes Iv–v
MAL-PDT + red light  
(22 J/cm2 and fluence rate 
was 34 mw/cm2) versus  
IPL (530–750 nm; fluence 
8–10 J/cm2)
3× (2 weeks);  
4 weeks
MAL-PDT + red light produced a more 
rapid response in I and NI lesions than  
IPL, but both had satisfactory results.  
Decrease fluence for Fitzpatrick skin  
type Iv–v given increased risk of  
postinflammatory hyperpigmentation.
Shaaban  
et al177 
2012
30 Controlled; nodulocystic 
and inflammatory acne 
vulgaris on face and back
IL-ALA versus IPL (560 nm, 
fluence 26 J/cm2, 15 msec 
pulse, 2–3 passes) alone; 
30 minutes
3× (1 week);  
1 month
IL-ALA . IPL alone: inflammatory lesion  
count was less in IL-ALA. Recurrence after 
1 month: 16.67% IL-ALA, 100% IPL only.
Haedersdal  
et al178 
2008
12 Split-face, randomized,  
controlled; Fitzpatrick  
skin type I–III,  
inflammatory lesions
MAL-LPDL versus LPDL 
(595 nm, 7.5 J/cm2, 10 msec, 
2 passes); 3 hours
3× (2 weeks);  
12 weeks
MAL-LPDL . LPDL alone but not  
powered to study efficacy of LPDL alone;  
median reduction of inflammatory lesions: 
80%  MAL-LPDL, 67% LPDL.
Sadick179 
2010
20 Split-face, randomized;  
moderate-to-severe acne
ALA-KTP versus KTP 
(532 nm) only
3× (4 weeks) Improvement in acne: 52% ALA-KTP,  
32% KTP.
Barolet and 
Boucher180 
2010
10 Split-face/back;  
randomized, controlled,  
investigator-blinded
Pretreatment with infrared 
LeD (970 nm) and ALA- 
PDT + LeD (630 nm)  
versus LeD (630 nm) only
Once; 4 weeks Inflammatory lesion reduction: 73% IR +  
ALA-PDT + LeD, 38% LeD. Improvement 
in clinical severity and reduction of NI  
lesions with IR + ALA-PDT (P=0.027 and  
P=0.037, respectively).
Yeung  
et al181 
2007
23 Split-face, randomized,  
single-blind; Fitzpatrick  
skin phototypes Iv or v,  
moderate acne
16% MAL-IPL versus IPL 
(530–750 nm, double pulses, 
2.5 msec) only versus  
placebo; 30 minutes
4× (3 weeks);  
12 weeks
Control . MAL-IPL . IPL only: reduction 
of inflammatory lesions: 88% control,  
65% MAL-IPL, 23% IPL (not significant).  
Reduction of noninflammatory lesions: 
38% MAL-IPL (P=0.05), 44% IPL (P=0.01);  
15% increase in control group (P=0.36).
Akaraphanth 
et al103 
2007
20 Split-face; moderate- 
to-severe acne
10% ALA-PDT versus blue 
light (415 nm, 40 mw/cm2,  
48 J/cm2); 1 hour
4× (1 week);  
16 weeks
Reduction of inflammatory lesions: 71.1%  
ALA-PDT, 56.7% blue light alone (not  
significant). No significant difference in  
lipid level.
Rojanamatin  
and 
Choawawanich182 
2006
14 Split-face 20% ALA-IPL versus IPL  
(560–590 nm, 25–30 J/cm2, 
double pulse) only;  
30 minutes
3× (3–4 weeks);  
12 weeks
Reduced lesion count 87.7% ALA-IPL,  
66.8% IPL only (difference not significant).
Hörfelt  
et al105 
2006
30 Split-face; blinded,  
prospective, randomized, 
placebo-controlled;  
moderate-to-severe acne
16.8% MAL-PDT versus 
placebo; 3 hours
2× (2 weeks);  
10 weeks
MAL-PDT . placebo: inflammatory lesion 
reduction: 54% MAL-PDT, 20% placebo.  
Difference in NI lesions not significant.
wiegell and 
wulf106 
2006
36 Randomized, controlled,  
investigator-blinded
16.8% MAL-PDT versus 
placebo; 3 hours
2× (2 weeks);  
12 weeks
MAL-PDT . placebo: inflammatory  
lesion reduction: 68% MAL-PDT, 0%  
control. No improvement in NI lesions.
wiegell and 
wulf98 
2006
15 Split-face; randomized,  
controlled, investigator- 
blinded
20% ALA-PDT versus 16.8%  
MAL-PDT; both with red  
light (630 nm, 37 mw/cm2,  
34 J/cm2); 3 hours
Once; 12 weeks A 59% decrease in inflammatory lesions  
but no significant difference between  
MAL and ALA.
Santos  
et al183 
2005
13 Split-face; I and NI  
lesions
20% ALA-IPL versus IPL  
(560 nm, 26 J/cm2, double  
pulse) alone; 3 hours
2× (2 weeks);  
8 weeks
ALA-IPL . IPL alone: ALA-IPL visible  
improvement (76.9%), IPL alone returned 
to baseline of facial acne.
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Table 1 (Continued)
Reference N Type of trial; study  
population/type
Light source (dose);  
incubation time
Session number  
(interval); follow-up
Results
Hong and  
Lee184 
2005
8 Split-face 20% ALA-PDT + red light  
(630±63 nm, 30 mw/cm2,  
18 J/cm2) versus placebo;  
4 hours
Once; 6 months Inflammatory lesion reduction: 41.9%  
ALA-PDT, 15.4% placebo. Reductions  
in noninflammatory lesions were not  
statistically significant.
Pollock  
et al101 
2004
10 Controlled; mild-to- 
moderate acne on the  
back
20% ALA-PDT versus red  
light (635 nm, 25 mw/cm2,  
10 J/cm2); 3 hours
3× (1 week); 3 weeks Reduction in inflammatory acne lesions  
after second treatment at ALA-PDT site  
but not other sites or treatments.
Goldman  
and Boyce185 
2003
22 Controlled; mild-to- 
moderate acne
20% ALA-PDT versus  
blue light (417±5 nm,  
10 mw/cm2, 3.6 J/cm2) only; 
15 minutes
2×; 2 weeks Inflammatory lesion reduction: 68% ALA- 
PDT, 40% blue light.
Hongcharu  
et al99 
2000
22 Randomized; mild-to- 
moderate inflammatory  
acne
20% ALA-PDT + red light  
versus light alone  
(550–570 nm, 150 J/cm2)  
versus placebo; 3 hours
Randomized to 1×  
versus 4× (1 week);  
20 weeks
ALA-PDT 4 sessions . ALA-PDT  
1 session . red light alone . placebo. 
Histology: sebaceous glands smaller after  
ALA-PDT.
Papageorgiu 
et al186 2000
107 Randomized; mild-to- 
moderate acne
Blue light (415 nm) versus  
mixed blue and red light  
(415 nm and 660 nm) versus  
5% benzoyl peroxide versus 
cool white light; 15 minutes
Daily × (12 weeks);  
8 weeks
Mixed blue-red . other treatments.  
At 8 weeks: 76% improvement in  
inflammatory lesions with blue-red light,  
greater than blue light and benzoyl  
peroxide (% not reported); 58%  
improvement in comedones with blue- 
red light (not significant).
Abbreviations: I, inflammatory; NI, noninflammatory; IL, intralesional; PDT, photodynamic therapy; ALA, aminolevulinic acid; MAL, methyl aminolevulinate; IPL, intense 
pulsed light; LPDL, long-pulsed dye laser; LeD, light-emitting diode; IR, infrared; KTP, potassium titanyl phosphate.
MAL-PDT in acne
MAL-PDT followed by red light has been well documented 
in the literature. One split-face study (n=30) used MAL 
with a 3-hour occlusion followed by red light, and showed 
a statistically significant median reduction in inflammatory 
lesion count at 12 weeks (54%) when compared with pla-
cebo (20%; 95% confidence interval 8%–50%).105 Another 
study (n=21) compared the use of MAL-PDT with the same 
regimen (3-hour occlusion and red light) versus placebo, 
and reported a median 68% reduction (P=0.0023) of inflam-
matory lesions upon clinical examination at 12 weeks post 
treatment. However, there was no significant difference in 
noninflammatory lesions.106 Interestingly, one study (n=16) 
concluded that a diluted concentration of 4% MAL resulted 
in similar efficacy (average 66% reduction for inflamma-
tory lesions) with reduced side effects (most commonly, 
pain), and this formulation may be a more cost-effective 
strategy.107
Other photosensitizers
Other topical photosensitizers, which have been studied less 
extensively, include indocyanine green (or methylene blue) 
and indole-3-acetic acid.32,33,108–113 Indole-3-acetic acid in 
particular may have an important role in clinical practice, 
primarily because patients receiving indole-3-acetic acid 
for acne experience less pain. It also has promising practical 
aspects, requiring shorter incubation times whilst producing 
equivalent efficacy (Table 2).
Rosacea
Rosacea, sometimes termed “adult acne”, although similar 
in appearance to acne, has a different pathophysiology. 
Common current treatments include topical metronidazole, 
topical azelaic acid, oral tetracyclines, and most recently, 
topical alpha-2 adrenergic agonists. Recent evidence sug-
gests that rosacea may represent an altered immune reactivity 
to the microbes of the skin.114
The use of ALA-PDT in rosacea is primarily anecdotal, 
with few randomized controlled studies published thus far. 
MAL-PDT with red light has been shown to improve the 
appearance of rosacea, in particular papulopustular lesions 
when compared with the erythematotelangiectatic types.115 
One small, prospective study (n=4) demonstrated increased 
efficacy using PDT with long-pulsed dye laser (LPDL) versus 
LPDL alone in the treatment of inflammatory papulopustular 
rosacea.116 However, in a controlled study, the long-term 
benefit of MAL-PDT with LPDL compared with LPDL alone 
demonstrated no difference.116 This study does not rule out the 
possibility that other light sources may work in combination 
with ALA to treat rosacea effectively.Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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Figure 3 Improvement in a 27-year-old woman with inflammatory papules on the face. (A) Before treatment (top row). (B) Three-month follow-up after one treatment of 
MAL-PDT with red light, ie, 200 J/cm2, and 180-minute incubation under occlusion (bottom row).
Abbreviations: MAL, methyl aminolevulinate; PDT, photodynamic therapy.
Table 2 Use of indole-3-acetic acid and photodynamic therapy in treatment of acne
Reference Indication n Type of trial Treatment regimen;  
session number (interval)
Results
Kwon  
et al187 2013
Seborrheic  
dermatitis
23 Prospective, single- 
blind
IAA-PDT with green light  
(520 nm); 2× (1 week)
Sebum excretion significantly reduced at 
week 2 until week 6.
Huh  
et al188 2012
Acne vulgaris 25 Prospective IAA-PDT 15 minutes of  
occlusion, and green light for  
15 minutes; 5× (1 week)
Inflammatory and noninflammatory acne 
lesions were significantly decreased; sebum 
secretion and erythema were reduced; 
histopathologic reduction of inflammation.
Jang  
et al32 2011
Acne vulgaris 34 Prospective, single- 
blind, split-face
IAA-PDT with green light  
(520 nm) on half of the face  
and ICG with near-infrared  
radiation (805 nm) on the  
other half; 5× (1 week)
Inflammatory . noninflammatory acne 
lesions decreased; sebum secretion 
decreased; up to 3 months of follow-up for 
subjective satisfaction score; no statistically 
significant difference between the two 
treatments.
Na  
et al189 2011
Acne vulgaris 14 Prospective, biopsies 
on nude mice as well
IAA-PDT with green light  
(520 nm); 3× (2 week)
Growth of Propionibacterium acnes and 
Staphylococcus aureus was significantly 
suppressed; treated skin showed 
destruction of follicular ostia epithelium; 
no significant difference between 4-hour 
and 30-minute incubation; inflammatory 
lesions and sebum secretion were reduced.
Abbreviations: IAA, indole-3-acetic acid; ICG, indocyanine green; PDT, photodynamic therapy.Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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Microbes such as Demodex and Staphylococcus 
epidermidis have both been implicated in the pathogenesis of 
rosacea. One in vitro study demonstrates the ability of ALA-
PDT to decrease the biofilm of Staphylococci and another 
study demonstrated eradication of Demodex.117,118 In contrast, 
one clinical study suggested that there was no change in the 
bacterial flora of the skin after MAL-PDT.119
Unlike acne, the results of PDT on rosacea are inconclu-
sive at best. In general, the papulopustular elements seem 
to respond as compared with the erythematotelangiectatic 
elements. Patients should be warned that some may experi-
ence increased erythema after the therapy.
Other inflammatory disorders
Hidradenitis suppurativa has been treated with MAL-
PDT with excellent results, although negative studies also 
exist.120,121 PDT has also been reported to have an effect on 
morphea and actinic cheilitis.122
PDT in microbial diseases
viruses
Human papillomaviruses can manifest in a variety of ways, 
including as warts, cervical carcinoma, anogenital SCC, and 
papillomatosis. Warts are the most common entity of this 
virus. Treatment of warts (verrucae vulgaris, verrucae plana) 
includes surgical excision, cryotherapy, curettage, surgical 
excision, topical cytotoxic medications (5-fluorouracil, dinitro-
chlorobenzene), intralesional bleomycin, infrared coagulation, 
CO2 laser therapy, PDL, PDT, and electrosurgery. However, 
some lesions remain recalcitrant to therapy, and many com-
monly recur after successful treatment. ALA-PDT has been 
shown to successfully treat cutaneous warts without significant 
side effects and excellent cosmetic results in several studies. 
Reported clearance rates are as high as 88%. The clearance rate 
seems proportionate to the size of the warts, and mean treat-
ment time.123 ALA-PDT with white light (halogen lamp; 250 W 
Osram; delivered via slide projector) was found to be more 
efficacious than red or blue light and standard cryotherapy.124 
One case report demonstrated the use of fractional resurfacing 
to aid PDL-PDT delivery in a recalcitrant plantar wart.125
Other virus-mediated lesions treated successfully with 
PDT have been reported. Epidermodysplasia verruciformis 
was successfully treated with ALA-PDT. Within 3 weeks, 
the lesions had completely healed without scarring after 
one   treatment.126 Eradication of human papillomavirus 
in genital warts (condyloma acuminata) has been shown 
with use of PDT in conjunction with 5-ALA, Photolon™ 
  (Belmedpreparaty, Minsk, Republic of Belarus), polyhe-
matoporphyrin, and YAG-OPO laser irradiation or CO2 laser 
vaporization.127–133 Finally, there are reports of successful 
treatment with PDT for cases of molluscum contagiosum and 
herpes simplex virus.134,135 In this setting, PDT is still working 
primarily in an antiproliferative manner. The advantage con-
tinues to be the ability to treat a large surface area, and with 
minimal scarring. In terms of recurrence rates, it is unclear 
whether PDT or CO  2 laser therapy is superior.133,136
Onychomycosis
Past clinical trials have suggested that tinea cruris, tinea pedis, 
and interdigital mycoses recur frequently when treated with 
ALA-PDT.137–139 However, more recently, one clinical trial 
(n=30) used chemical avulsion (occlusion with urea for ten 
consecutive nights prior to PDT) and 20% ALA-PDT (3-hour 
incubation) followed by red light therapy, and demonstrated 
a 43.3% cure rate at 12-month follow-up, which dropped to 
36.6% at 18-month follow-up.140 Two other case series reported 
complete resolution of fungal infection with PDT. One case 
demonstrated successful treatment of subungual onychomycosis 
after occlusion with urea for 7 days followed by MAL-PDT with 
broadband red light (37 J/cm2). This was repeated every 2 weeks 
for a total of three treatments. In this case, Trichophyton rubrum 
was the causative organism and previously had been demon-
strated to be sensitive to PDT in vitro. Nondermatophyte molds 
have also been cleared with MAL-PDT and red light.141,142
Other nonhematoporphyrin-derived photosensitizers (Syls-
ens B being the most effective) have also been shown to be effi-
cacious in the treatment of onychomycosis.143,144 Major concerns 
regarding effective drug penetration through thick, hyperkera-
totic ungual barriers have led to introduction of new delivery 
methods involving iontophoretic and ultrasound devices, which 
enable increased nail bed permeability.145,146 Most recently, one 
patient with treatment-resistant onychomycosis was success-
fully pretreated with a micro motor pneumatic diamond drill 
device and subsequent ALA-PDT with red light.147
Leishmaniasis
Cutaneous leishmaniasis is the most common form of 
leishmaniasis, and is transmitted by sand flies. Various case 
reports and series have documented successful treatment of 
cutaneous leishmaniasis using PDT. Studies have also shown 
PDT to be effective in the treatment of antibiotic-resistant 
cutaneous leishmaniasis, further strengthened by another 
study comparing the efficacy of PDT versus paromomycin 
or methylbenzethonium chloride.148–151 Individual cases 
demonstrating successful treatment using MAL-PDT include 
an 8-year-old Italian girl and an Austrian patient infected Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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with Leishmania major.91,152 Clinicians can consider PDT 
as a safe and efficacious treatment option for cutaneous 
leishmaniasis.
Other infections
Erythrasma is the cutaneous manifestation of Corynebacterium 
minutissimum, characterized by heterogeneous coral-red fluo-
rescence due to presence of endogenous porphyrins in the 
bacteria. PDT with red light irradiation and without an exog-
enous photosensitizer achieved complete clearance in 23% 
of lesions (3/22) and partial clearance in 82% of lesions 
(18/22).153 Reports of unsuccessful ALA-PDT in the treatment 
of Candida albicans intertrigo have been documented.139
PDT in proliferative disease
Photoaging/antiaging/photorejuvenation
Photoaging is characterized by increased skin elastosis associated 
with degraded collagen. Clinically, one can observe irrevers-
ible skin hyperpigmentation, ephelides, lentigines, abnormal 
elastic fibers, telangiectasias, sebaceous gland hyperplasia, 
and rhytids.154,155 Histopathologically, dilated blood vessels 
and increased pigment are found accumulated in the papillary 
dermis.156–160 Current treatments for photorejuvenation include 
retinoids, laser resurfacing, chemical peels, and various light 
therapies (Table 3). Photorejuvenation has been frequently 
observed in patients undergoing PDT for other disease entities, 
and therefore has become an area of further investigation.
PDT with blue light
ALA-PDT with blue light has been reported to improve 
skin elasticity, as well as skin texture, pigmentation, fine 
lines, and complexion.161–163 Deep wrinkling and mottled 
hyperpigmentation have not been reported to change fol-
lowing treatment.
PDT with red light
One study (n=20) revealed a statistically significant improve-
ment (P,0.05) after administration of MAL-PDT and red 
light with respect to mottled hyperpigmentation, fine lines, 
skin roughness, and sallowness, but no improvement of deep 
wrinkles, superficial angiogenesis, facial erythema, and seba-
ceous gland hyperplasia. To quantify epidermal and dermal 
changes during PDT, an analysis using high-resolution echog-
raphy showed increased skin thickness, which the authors 
postulated to be caused by increased collagen synthesis.164 
One investigator-blinded study with a 2-month follow-up 
revealed moderate improvement in fine lines, tactile rough-
ness, and skin tightness, especially on the half of the face that 
had a 3-hour incubation with MAL compared with a one-hour 
incubation. In contrast with other studies, there was no change 
in mottled hyperpigmentation, and consistent with other 
reports, no improvement of telangiectasias.165 A larger clinical 
split-face trial (n=94) demonstrated superiority in terms of 
improvement in global photodamage using MAL-PDT with 
red light versus placebo.166 Opposing studies exist, however, 
including one study that compared blue light versus red light 
and MAL-PDT. In this study, no difference in efficacy was 
observed in photodamaged skin.167
PDT with intense pulsed light
One retrospective split-face study (n=20) compared pretreat-
ment with 5-ALA (5-ALA first treatment, IPL only for last 
two treatments) on one half of the patient’s face versus IPL 
treatment alone. After three treatments, greater subjective 
improvement was observed in the ALA-IPL arm in terms of 
global photoaging, mottled pigmentation, and fine lines.168 
Pretreatment with ALA did not improve observed sallow-
ness or tactile roughness at one-month follow-up after five 
treatments. Following this, another split-face study (n=13) 
reported similar results, with improved appearance of crow’s 
feet (55% versus 29.5%), tactile skin roughness (55% versus 
29.5%), mottled hyperpigmentation (60.3% versus 37.2%), 
and telangiectasias (84.6% versus 53.8%) in the ALA-IPL 
group.169 A major advantage of IPL compared with irradiation 
with a light-emitting diode is less time expenditure and less 
painful effects of heat delivery due to shorter intense expo-
sure times.170 Clinicians should be aware that heat delivered 
by IPL may cause destruction of hair follicles, so it should be 
used with caution, especially in men with facial hair.
Mechanisms supporting PDT-induced photorejuvenation 
have been proposed. Studies involving punch biopsies after ALA-
IPL demonstrate an increase in type I collagen.   Interestingly, 
Orringer et al used biomarkers to examine the molecular effects 
of ALA-PDT and PDL, and showed upregulation of Ki-67 (an 
immunohistochemical biomarker of keratinocyte proliferation), 
along with elevated levels of procollagen I and procollagen III, 
indicating new formation of collagen.159
Other proliferative conditions
PDT has been shown to reduce type I collagen synthesis 
and fibroblast activity in vitro, thus potentially having a 
role in the treatment of scars.171 Several groups have dem-
onstrated improvement in the skin flexibility of hypertro-
phic scars using MAL-PDT.172,173 One recent study (n=20) 
demonstrated that three treatments of MAL-PDT were 
effective in reducing formation of keloid scars, which were Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
157
Photodynamic therapy in dermatology
less than 2 mm in height. There was a 95% (19/20) recur-
rence rate at 9-month follow-up.174 Furthermore, another 
study (n=21) showed improvement in post-surgical scar 
appearance, which directly correlated with the number of 
ALA/MAL-PDT sessions.175 PDT represents a promis-
ing, noninvasive treatment, but more definitive studies are 
required to elicit its role and the regimen required in the 
treatment of cicatrix.
Concluding remarks
PDT is a mainstay of treatment for actinic keratoses and 
superficial nonmelanoma skin cancers, and has been 
demonstrated to be an increasingly popular option for acne. 
With the advent of nanoemulsions and patch-ALA, recent 
advances have focused on improved vehicles and delivery. 
Improving standardization of ALA delivery and decreas-
ing pain during the treatment are advances that will further 
popularize this modality. PDT is more frequently utilized in 
Europe as compared with the US. This discrepancy likely 
reflects the poor reimbursement rates for PDT in the US. 
Well controlled studies are needed to demonstrate the efficacy 
of PDT in order to justify its use, and hopefully convince 
insurance companies that this viable treatment option with 
a low side effect profile and high cosmetic outcome is worth 
Table 3 Comparative studies of PDT light sources in photorejuvenation/photoaging
Reference n Type 
of study
Light sources (light doses); 
incubation times
Session number  
(interval); follow-up
Results
Haddad et al190  
2011
24 Comparative 20% ALA-IPL (20, 25, 40, and 
50 J/cm2) versus IPL only; 
2 hours
Once; 8 weeks Photorejuvenation did not seem to  
improve with increasing IPL fluence  
levels.
Xi et al191  
2011
24 Split-face,  
prospective,  
controlled
5% and 10% ALA, IPL (560 nm 
or 590 nm, 14–20 J/cm2,  
3.5–4 msec, double or triple  
pulses); 1 hour
3× (4 weeks);  
2 months
ALA-IPL . IPL: global score: 50%  
ALA-IPL, 12.5% IPL only. Fine lines:  
70.8% ALA-IPL, 33.3% IPL only. Coarse  
wrinkles: 50% ALA-IPL, 12.5% IPL only.  
No significant difference with respect to  
mottled pigmentation and skin roughness.
Kosaka et al192  
2010
16 Split-face 5% ALA + IPL (500–670 nm  
and 870–1,400 nm, 23–30 J/cm2, 
20 msec, single pulses); 2 hours
3× (4 weeks);  
3 months
Significant improvement of signs of skin  
aging, equal on both sides (ALA-IPL and  
IPL alone). However, 75% of patients found 
ALA-IPL more effective than IPL alone.
Bjerring  
et al193  
2009
37 Split-face, 
prospective,  
randomized
0.5% liposome-encapsulated  
ALA-IPL (530–750 nm,  
rejuvenation filter, 6–7 J/cm2,  
double pulses of 2.5 msec)  
versus ALA-IPL (400–720 nm, 
3.5 J/cm2, 30 msec)
3× (3 weeks);  
3 months
ALA-IPL (530–750 nm) versus ALA-IPL  
(400–720 nm): significant reduction of  
perioral and periorbital wrinkles on  
both sides. Pigmentation, erythema, and  
telangiectasias better with IPL (530–750 nm).
Ruiz-Rodriquez 
et al165 
2008
10 Split-face,  
randomized,  
prospective
16% MAL-PDT + red light;  
1 hour versus 3 hours
3×; 2 months Moderate improvement in fine lines, tactile 
roughness, and skin tightness in both groups, 
greater improvement in 3-hour group.
Ruiz-Rodriquez 
et al194 
2007
4 Split-face Fraxel® SR laser pretreatment  
then MAL-PDT + red light  
versus pretreatment only;  
3 hours
2 Fraxel SR laser  
(3 weeks) then once  
MAL-PDT; 12 weeks
Greater improvement in pretreatment + 
MAL-PDT rather than pretreatment only 
(not significant).
Gold et al169  
2006
13 Split-face,  
prospective
20% ALA-IPL versus IPL  
(550–570 nm, 34 J/cm2) alone;  
30–60 minutes
3× (1 month);  
3 months
ALA-IPL . IPL alone. Crow’s feet: 55% 
ALA-IPL, 29.5% IPL alone. Tactile skin 
roughness: 55% ALA-PDT-IPL, 29.5% IPL 
alone. Mottled hyperpigmentation: 60.3% . 
37.2% IPL alone. Telangiectasias: 84.6%  
ALA-PDT- IPL, 53.8% IPL alone.
Dover et al195  
2005
20 Split-face,  
prospective,  
randomized
20% 5-ALA + IPL versus IPL  
(515–1,200 nm, 23–28 J/cm2)  
alone; 30–60 minutes
3 split face ×  
(3 weeks) then  
2× IPL only  
(3 week); 1 month
ALA-IPL . IPL alone. Photoaging scale: 80% 
ALA-IPL, 45% IPL alone. Hyperpigmentation: 
85% ALA-IPL, 20% IPL alone. Fine lines: 60% 
ALA-IPL, 25% IPL alone.
Alster et al196  
2005
10 Split-face 5-ALA-IPL versus IPL alone 
(560 nm); 1 hour
2× (4 weeks);  
6 months
Higher clinical global improvement scores 
(by photography) 5-ALA + IPL . IPL alone.
Note: Fraxel® (formerly Fraxel SR750, Reliant Technologies Inc, Palo Alto, CA, USA).
Abbreviations: PDT, photodynamic therapy; ALA, aminolevulinic acid; MAL, methyl aminolevulinate; IPL, intense pulsed light.Clinical, Cosmetic and Investigational Dermatology 2014:7 submit your manuscript | www.dovepress.com
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investing in. The field of PDT will continue to expand as new 
photosensitizers emerge in the market. Finally, combination 
therapy, particularly with imiquimod, will be the new standard 
of care for PDT in patients with skin cancer.
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